Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. FDA greenlight for esketamine sheds light on ketamine’s potential
  2. BMS’ Opdivo plus Yervoy for RCC to be available through NHS Scotland
  3. Everest Medicines to commercialise Calliditas’ Nefecon in Greater China and Singapore
  4. FDA approves first drug for episodic cluster headaches
  5. Berkeley scientists discover Chinese CRISPR babies at higher risk of early death

Latest Content

FDA greenlight for esketamine sheds light on ketamine’s potential

In March, the FDA approved Janssen Pharmaceuticals’ depression drug esketamine, a form of ketamine for use as a treatment for depression. Billed as the most exciting antidepressant in decades, the drug has an entirely new mechanism of action. So what does esketamine offer, and why is the FDA so sure the benefits outweigh the risks?

BMS’ Opdivo plus Yervoy for RCC to be available through NHS Scotland

Scotland’s healthcare pricing regulator the Scottish Medicines Consortium (SMC) has decided to fund Bristol Myers-Squibb (BMS)’s Opdivo (nivolumab) plus Yervoy (ipilimumab) for use in NHS Scotland for renal cell carcinoma (RCC) patients, who are previously untreated and considered to be of intermediate or poor prognostic risk.

Genentech receives FDA approval for Polivy to treat DLBCL

Genentech has received accelerated approval from the US Food and Drug Administration (FDA) for the use of Polivy (polatuzumab vedotin-piiq) in combination with bendamustine and rituximab (BR) to treat diffuse large B-cell lymphoma (DLBCL) in adults.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top